2015 · Journal of clinical pharmacology · paywalled
Dried blood spot analysis for therapeutic drug monitoring of pazopanib
de Wit et al.
The finding, in our words
Dried blood spot sampling of pazopanib showed clinically acceptable agreement with plasma concentrations in 12 patients, with 92.6% of paired samples falling within predefined acceptance limits. The method supports decentralised therapeutic drug monitoring of this oncology agent, though validation of cards prepared by patients themselves remains needed.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Levens et al., Clinical Pharmacokinetics (paywalled) · source ↗
A 2025 review maps 28 microsampling devices, from dried spots and volumetric absorptive tips to upper-arm liquid capillary collectors, and names what a laboratory must control before their results are used: the haematocrit effect in non-volumetric dried samples, interstitial fluid from finger milking, volume, haemolysis and transport stability. Regulators on both sides of the Atlantic ask for the same two things, a device the patient can use safely and a sample fit for the test.
LC-MS/MS measurement of imatinib and its active metabolite from volumetric dried blood spots collected via HemaXis DB10 and Capitainer B demonstrated analytical precision across hematocrits from 22% to 55% alongside 43-day ambient stability. Clinical evaluation across 52 paired samples showed high agreement with plasma concentrations, verifying both devices as reliable options for decentralised therapeutic drug monitoring.
Orleni et al., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (paywalled) · source ↗
The authors developed and validated an LC-MS/MS method for measuring three PARP inhibitors in both plasma and dried blood spots. They found strong agreement between the two matrices for olaparib and niraparib, suggesting DBS could support therapeutic drug monitoring for these oncology drugs in decentralised settings.
A fast, validated LC-MS/MS method quantifies lenvatinib from 10 µL dried blood spots with good agreement to plasma concentrations (R² ≥ 0.996) in patients with hepatocellular carcinoma. The method controls for haematocrit effects and could enable decentralised therapeutic drug monitoring of this oncology therapy.
Zanchetta et al., Journal of pharmaceutical and biomedical analysis (paywalled) · source ↗